Skip to main content
. 2016 May 30;15(5):861–871. doi: 10.1111/acel.12495

Figure 3.

Figure 3

NS398 administration decreases the expression of APH‐1α/1β via inhibiting the production of PGI 2 in APP/PS1 transgenic mice. The APP/PS1 transgenic mice at 1 month of age received NS398 (50 μg kg−1 day−1) for 5 months before harvesting brain slices (n = 3) (a, c, e, f, i, j). In selected experiments, the APP/PS1 transgenic mice at the 6 months of age were injected (i.c.v.) with NS398 (2 μg/5 μL). The brains were then collected and sectioned after 24 h (n = 8) (b, d, g, h, k, l). The production of PGI 2 was determined by PGI 2 enzyme immunoassay kits (a, b). The immunoreactivity of APH‐1 was determined by immunohistochemistry using an anti‐APH‐1 antibody (c, d). APH‐1α/1β mRNA and protein expression levels were determined by qRT–PCR and Western blots, respectively (e–h). The production of sAPPα and sAPPβ was determined by Western blots (i–l). The production of Aβ1–42 was determined by Aβ1–42 ELISA kits (i‐l). The data represent the means ± SE of three independent experiments. *P < 0.05 with respect to WT mice. # P < 0.05 compared to APP/PS1 transgenic mice.